Shares of ERYTECH Pharma (NASDAQ: ERYP) have surged premarket on news that the US Food and Drug Administration (FDA) has granted eryaspase Fast Track designation.
The designation is to treat acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).
“This is yet another significant milestone and meaningful inflection point in advancing our lead product candidate eryaspase, further supporting our recently announced intention to submit a BLA for eryaspase in hypersensitive ALL patients,” said Gil Beyen, CEO of ERYTECH.
“We believe that the FDA’s Fast Track designation for eryaspase underscores its potential to address this high unmet medical need.”
The company recently confirmed its intention to submit a Biologics License Application (BLA) for eryaspase in the fourth quarter of 2021, pending successful completion of the remaining steps.
In April 2020, eryaspase was also granted Fast Track designation to develop a second-line treatment of patients with metastatic pancreatic cancer.
On that day, its shares gained 32.3% before falling in the days following. ERYTECH shares are currently up 68% premarket at $6.91.
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .
Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.